Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Primary Central Nervous System Neoplasm”

137 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 137 results

Early research (Phase 1)Ended earlyNCT00112619
What this trial is testing

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsCarcinoma of Unknown PrimaryLeukemia+2 more
Pediatric Brain Tumor Consortium 19
Not applicableEnded earlyNCT00726830
What this trial is testing

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Who this might be right for
Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemia+8 more
M.D. Anderson Cancer Center 1
Early research (Phase 1)Study completedNCT00049712
What this trial is testing

Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma

Who this might be right for
LymphomaSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific
University of Wisconsin, Madison
Early research (Phase 1)Ended earlyNCT00004058
What this trial is testing

12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
University of Medicine and Dentistry of New Jersey
Early research (Phase 1)Study completedNCT01231919
What this trial is testing

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Leukemias of Ambiguous LineageAcute Myeloid Leukemia/Transient Myeloproliferative Disorder+48 more
National Cancer Institute (NCI) 45
Early research (Phase 1)Study completedNCT01460134
What this trial is testing

CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Who this might be right for
CD27 Expressing B-cell Malignancies for Example Hodgkin's LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+7 more
Celldex Therapeutics 90
Early research (Phase 1)Study completedNCT01076530
What this trial is testing

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Who this might be right for
Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Embryonal Tumor+31 more
National Cancer Institute (NCI) 27
Early research (Phase 1)Study completedNCT00045500
What this trial is testing

UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma

Who this might be right for
LymphomaUnspecified Adult Solid Tumor, Protocol Specific
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT05278208
What this trial is testing

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

Who this might be right for
High Grade GliomaMeningiomaEmbryonal Tumor+10 more
Nationwide Children's Hospital 65
Early research (Phase 1)Study completedNCT00503724
What this trial is testing

Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors

Who this might be right for
Brain and Central Nervous System TumorsNeuroblastoma
Pediatric Brain Tumor Consortium 32
Testing effectiveness (Phase 2)Study completedNCT02052648
What this trial is testing

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Who this might be right for
Glioblastoma MultiformeGliomaGliosarcoma+1 more
NewLink Genetics Corporation 160
Not applicableEnded earlyNCT00965861
What this trial is testing

SCRI Tissue Testing Registry

Who this might be right for
MelanomaMyelodysplastic SyndromeMultiple Myeloma+1 more
SCRI Development Innovations, LLC 20
Testing effectiveness (Phase 2)UnknownNCT05092802
What this trial is testing

The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment

Who this might be right for
Brain Tumor, Primary
Shanghai Henlius Biotech 40
Testing effectiveness (Phase 2)Study completedNCT02301364
What this trial is testing

Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Who this might be right for
LymphomaPrimary Central Nervous System LymphomaRecurrent/Refractory Secondary Central Nervous System Lymphoma
Memorial Sloan Kettering Cancer Center 4
Large-scale testing (Phase 3)Study completedNCT00008359
What this trial is testing

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

Who this might be right for
Cancer
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Study completedNCT01709435
What this trial is testing

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Who this might be right for
Recurrent Malignant Solid NeoplasmRecurrent MelanomaRecurrent Primary Central Nervous System Neoplasm+4 more
National Cancer Institute (NCI) 41
Testing effectiveness (Phase 2)Study completedNCT03213691
What this trial is testing

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+8 more
National Cancer Institute (NCI) 21
Early research (Phase 1)Study completedNCT02808650
What this trial is testing

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Who this might be right for
Childhood Solid NeoplasmRecurrent Malignant Solid NeoplasmRecurrent Primary Central Nervous System Neoplasm+2 more
Children's Oncology Group 30
Testing effectiveness (Phase 2)Study completedNCT00237627
What this trial is testing

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Who this might be right for
Breast CancerLeukemiaLymphoma+3 more
UNC Lineberger Comprehensive Cancer Center 107
Testing effectiveness (Phase 2)Active Not RecruitingNCT03698994
What this trial is testing

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent Ependymal TumorRecurrent Ewing Sarcoma+33 more
National Cancer Institute (NCI) 20
Load More Results